To read the full story, subscribe or sign in.

Talecris Opts for $3.1B Merger Instead of IPO

Aug. 14, 2008

Talecris Biotherapeutics Inc. said it is being acquired by Australian firm CSL Ltd. in a $3.1 billion cash merger that would form one of the largest plasma-derived therapeutics firms worldwide. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

BioWorld Science

Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...

Investors bet on transformative BCI tech for neuro disorders

BioWorld

An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....